Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05535946 · ClinicalTrials.gov registry record · Phase 3
ABTECT - Maintenance
A Phase 3 study of Ulcerative Colitis, sponsored by Abivax S.A..
- Active
- Registry status
- Phase 3
- Development phase
- 1,116
- Enrollment target
- 20
- Study locations
NCT05535946 is a Phase 3 study of Ulcerative Colitis that is active but no longer recruiting, run by Abivax S.A.. The registered enrollment target is 1,116 participants, below the 2,048-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT05535946, a Phase 3 study of Ulcerative Colitis, is active but no longer recruiting, sponsored by Abivax S.A..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,116 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors\]. This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ABX464
Study Locations (20)
California
- National Institute of Clinical Research - Bakersfield
- Kindred Medical Institute for Clinical Trials, LLC - Corona
- Aurora Care Clinic - Costa Mesa
- Citrus Valley Gastroenterology - Covina
- University of California (San Diego) - La Jolla
- Gastro Care Institute - Lancaster
- United Medical Doctors - Murrieta
- Hoag Memorial Hospital Presbyterian - Newport Beach
- California Medical Research Associates Inc. - Northridge
- Clinnova Research Solutions - Orange
Arizona
- Research Solutions of Arizona, PC - Litchfield Park
- Valleywise Health Medical Center - Phoenix
- GI Alliance - Sun City
- Del Sol Research Management, LLC - Tucson
- University of Arizona - Tucson
Alabama
- University of Alabama -Birmingham - Birmingham
- Digestive Health Specialists of the Southeast - Dothan
- Lakeview Clinical Research - Guntersville
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
- Applied Research Center of Arkansas - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,116 participants |
| Start Date | 2023-01-16 |
| Est. Completion | 2030-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05535946
The ClinicalTrials.gov registry entry for NCT05535946 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,048-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (46% lower). The listed sponsor is Abivax S.A., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05535946 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT05535946 about?
NCT05535946 is a clinical study titled "ABTECT - Maintenance". This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of...
What is the current status of trial NCT05535946?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,116 participants. The study started on 2023-01-16. Estimated completion is 2030-05.
What conditions does trial NCT05535946 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT05535946?
The interventions under investigation include: Placebo (DRUG), ABX464 (DRUG).
Who is sponsoring clinical trial NCT05535946?
This trial is sponsored by Abivax S.A., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05535946 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
RECRUITING · Phase 3
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RECRUITING · Phase 3
-
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
RECRUITING · Phase 3
-
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.